Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated: March 13, 2026, 8:28 am
Author: Getaka|Social: XLinkedIn
Stock Ticker - BSE: 500488 | NSE: ABBOTINDIA

Abbott India Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: March 13, 2026, 8:28 am

Market Cap 56,706 Cr.
Current Price 26,685
Intrinsic Value₹23,232.43
High / Low 37,000/26,000
Stock P/E37.2
Book Value 1,888
Dividend Yield1.78 %
ROCE46.2 %
ROE35.7 %
Face Value 10.0
PEG Ratio2.70

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Abbott India Ltd

Competitors

Stock Name ⇩Market Cap ⇩Current Price ⇩High / Low ⇩Stock P/E ⇩Book Value ⇩Dividend Yield ⇩ROCE ⇩ROE ⇩Face Value ⇩
Abbott India Ltd 56,706 Cr. 26,685 37,000/26,00037.2 1,8881.78 %46.2 %35.7 % 10.0
Laurus Labs Ltd 56,512 Cr. 1,047 1,141/51770.6 91.10.11 %9.47 %7.75 % 2.00
Biocon Ltd 63,572 Cr. 392 425/29577.4 2000.13 %6.25 %4.76 % 5.00
Glenmark Life Sciences Ltd 63,676 Cr. 2,256 2,298/1,33623.5 3400.11 %19.4 %15.8 % 1.00
Glenmark Pharmaceuticals Ltd 63,676 Cr. 2,256 2,298/1,33623.5 3400.11 %19.4 %15.8 % 1.00
Industry Average20,618.65 Cr1,089.4655.17201.810.38%16.35%15.16%6.10

All Competitor Stocks of Abbott India Ltd

Quarterly Result

MetricDec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales 1,3221,3431,4791,4941,4371,4391,5581,6331,6141,6051,7381,7571,724
Expenses 1,0101,0631,1241,1131,0491,1091,1671,1941,1781,1761,2931,2551,261
Operating Profit 312280355381388330391439436429446502463
OPM % 24%21%24%25%27%23%25%27%27%27%26%29%27%
Other Income 44505656568167607276737070
Interest 4433333224685
Depreciation 18171718181818181818191919
Profit before tax 335308390415422390437479488483493546509
Tax % 26%25%26%25%26%26%25%25%26%24%26%24%26%
Net Profit 247231290313311287328359361367366415376
EPS in Rs 116.16108.91136.59147.27146.35135.09154.36168.76169.78172.73172.18195.43176.93

Last Updated: March 3, 2026, 1:17 pm

Below is a detailed analysis of the quarterly data for Abbott India Ltd based on the most recent figures (Dec 2025) and their trends compared to the previous period:

  • For Sales, as of Dec 2025, the value is 1,724.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,757.00 Cr. (Sep 2025) to 1,724.00 Cr., marking a decrease of 33.00 Cr..
  • For Expenses, as of Dec 2025, the value is 1,261.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,255.00 Cr. (Sep 2025) to 1,261.00 Cr., marking an increase of 6.00 Cr..
  • For Operating Profit, as of Dec 2025, the value is 463.00 Cr.. The value appears to be declining and may need further review. It has decreased from 502.00 Cr. (Sep 2025) to 463.00 Cr., marking a decrease of 39.00 Cr..
  • For OPM %, as of Dec 2025, the value is 27.00%. The value appears to be declining and may need further review. It has decreased from 29.00% (Sep 2025) to 27.00%, marking a decrease of 2.00%.
  • For Other Income, as of Dec 2025, the value is 70.00 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2025) which recorded 70.00 Cr..
  • For Interest, as of Dec 2025, the value is 5.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 8.00 Cr. (Sep 2025) to 5.00 Cr., marking a decrease of 3.00 Cr..
  • For Depreciation, as of Dec 2025, the value is 19.00 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2025) which recorded 19.00 Cr..
  • For Profit before tax, as of Dec 2025, the value is 509.00 Cr.. The value appears to be declining and may need further review. It has decreased from 546.00 Cr. (Sep 2025) to 509.00 Cr., marking a decrease of 37.00 Cr..
  • For Tax %, as of Dec 2025, the value is 26.00%. The value appears to be increasing, which may not be favorable. It has increased from 24.00% (Sep 2025) to 26.00%, marking an increase of 2.00%.
  • For Net Profit, as of Dec 2025, the value is 376.00 Cr.. The value appears to be declining and may need further review. It has decreased from 415.00 Cr. (Sep 2025) to 376.00 Cr., marking a decrease of 39.00 Cr..
  • For EPS in Rs, as of Dec 2025, the value is 176.93. The value appears to be declining and may need further review. It has decreased from 195.43 (Sep 2025) to 176.93, marking a decrease of 18.50.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: February 26, 2026, 1:46 pm

MetricMar 2014n n 15mMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales 2,2762,2892,6142,9033,2983,6794,0934,3104,9195,3495,8496,4096,824
Expenses 2,0091,9772,2502,5052,7743,0743,3363,3883,8324,1434,3964,7144,984
Operating Profit 2673123653985256057579221,0881,2061,4531,6951,840
OPM % 12%14%14%14%16%16%18%21%22%23%25%26%27%
Other Income 494850571171131148177154248275289
Interest 0032429181916121123
Depreciation 22151416161760586670717275
Profit before tax 2953443984366216998039261,0801,2741,6181,8872,031
Tax % 33%34%36%37%35%36%26%25%26%25%26%25%
Net Profit 1982292552774014505936917999491,2011,4141,524
EPS in Rs 93.39107.75120.12130.19188.82211.93279.04325.04375.87446.80565.30665.64717.27
Dividend Payout % 25%29%29%31%29%31%90%85%73%73%73%71%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2015-20162016-20172017-20182018-20192019-20202020-20212021-20222022-20232023-20242024-2025
YoY Net Profit Growth (%)11.35%8.63%44.77%12.22%31.78%16.53%15.63%18.77%26.55%17.74%
Change in YoY Net Profit Growth (%)0.00%-2.73%36.14%-32.55%19.56%-15.25%-0.90%3.14%7.78%-8.82%

Abbott India Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 10 years from 2015-2016 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:11%
5 Years:9%
3 Years:9%
TTM:11%
Compounded Profit Growth
10 Years:20%
5 Years:19%
3 Years:21%
TTM:17%
Stock Price CAGR
10 Years:20%
5 Years:14%
3 Years:21%
1 Year:8%
Return on Equity
10 Years:30%
5 Years:32%
3 Years:34%
Last Year:36%

Last Updated: September 5, 2025, 2:01 pm

Balance Sheet

Last Updated: December 4, 2025, 2:16 am

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital 21212121212121212121212121
Reserves 7679161,1741,3661,6721,9872,4102,5812,7993,1673,6784,2123,990
Borrowings 00000017515315211383197182
Other Liabilities 3514364216797239329401,0861,2531,2541,4111,4871,501
Total Liabilities 1,1391,3741,6162,0662,4162,9413,5473,8404,2244,5565,1935,9175,694
Fixed Assets 989610811081105270251271237225336314
CWIP 1436212114101823
Investments 0000000000000
Other Assets 1,0401,2741,5051,9502,3332,8353,2753,5893,9524,3154,9585,5635,357
Total Assets 1,1391,3741,6162,0662,4162,9413,5473,8404,2244,5565,1935,9175,694

Below is a detailed analysis of the balance sheet data for Abbott India Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:

  • For Equity Capital, as of Sep 2025, the value is 21.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 21.00 Cr..
  • For Reserves, as of Sep 2025, the value is 3,990.00 Cr.. The value appears to be declining and may need further review. It has decreased from 4,212.00 Cr. (Mar 2025) to 3,990.00 Cr., marking a decrease of 222.00 Cr..
  • For Borrowings, as of Sep 2025, the value is 182.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 197.00 Cr. (Mar 2025) to 182.00 Cr., marking a decrease of 15.00 Cr..
  • For Other Liabilities, as of Sep 2025, the value is 1,501.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,487.00 Cr. (Mar 2025) to 1,501.00 Cr., marking an increase of 14.00 Cr..
  • For Total Liabilities, as of Sep 2025, the value is 5,694.00 Cr.. The value appears to be improving (decreasing). It has decreased from 5,917.00 Cr. (Mar 2025) to 5,694.00 Cr., marking a decrease of 223.00 Cr..
  • For Fixed Assets, as of Sep 2025, the value is 314.00 Cr.. The value appears to be declining and may need further review. It has decreased from 336.00 Cr. (Mar 2025) to 314.00 Cr., marking a decrease of 22.00 Cr..
  • For CWIP, as of Sep 2025, the value is 23.00 Cr.. The value appears strong and on an upward trend. It has increased from 18.00 Cr. (Mar 2025) to 23.00 Cr., marking an increase of 5.00 Cr..
  • For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
  • For Other Assets, as of Sep 2025, the value is 5,357.00 Cr.. The value appears to be declining and may need further review. It has decreased from 5,563.00 Cr. (Mar 2025) to 5,357.00 Cr., marking a decrease of 206.00 Cr..
  • For Total Assets, as of Sep 2025, the value is 5,694.00 Cr.. The value appears to be declining and may need further review. It has decreased from 5,917.00 Cr. (Mar 2025) to 5,694.00 Cr., marking a decrease of 223.00 Cr..

Notably, the Reserves (3,990.00 Cr.) exceed the Borrowings (182.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Reserves and Borrowings Chart

Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity + 1552152493071534996267279488931,2131,012
Cash from Investing Activity + -144-187-77-155-215-257-401-72-396-148-416182
Cash from Financing Activity + -42-58-80-90-102-143-217-582-637-639-745-925
Net Cash Flow -31-309162-16599873-8610752269

Free Cash Flow

MonthMar 2014n n 15mMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Free Cash Flow267.00312.00365.00398.00525.00605.00582.00769.00-151.00-112.00-82.00-196.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days 182120222927282121222022
Inventory Days 101107911071121068311094807092
Days Payable 38545610192116104116122109114110
Cash Conversion Cycle 807454284917814-6-8-243
Working Capital Days 363032216322107-7-8-1497
ROCE %39%40%38%34%41%37%35%35%38%41%46%46%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthMar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Promoters 74.99%74.99%74.99%74.99%74.99%74.99%74.99%74.99%74.99%74.99%74.99%74.99%
FIIs 0.19%0.19%0.19%0.18%0.18%0.18%0.17%0.17%0.16%0.16%0.16%0.19%
DIIs 8.61%8.77%8.83%8.73%8.91%8.81%9.00%9.01%8.91%9.18%9.11%9.00%
Public 16.20%16.05%16.01%16.09%15.92%16.01%15.86%15.85%15.94%15.67%15.74%15.83%
No. of Shareholders 72,08669,58268,88572,25269,38271,58869,44967,89269,93467,58471,19975,801

Shareholding Pattern Chart

No. of Shareholders

Abbott India Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)Previous Number of SharesPrevious DatePercentage Change
SBI Large & Midcap Fund 274,878 2.02 757.7155,0002025-10-30 02:04:4977.34%
Nippon India Multi Cap Fund 109,953 0.62 303.09105,9532026-02-23 07:02:123.78%
Nippon India Pharma Fund 74,187 2.6 204.568,6772026-01-25 01:59:438.02%
SBI Innovative Opportunities Fund 60,032 3.12 165.48N/AN/AN/A
SBI MNC Fund 60,000 2.95 165.3975,0002026-02-23 07:02:12-20%
Franklin India Mid Cap Fund 52,304 1.18 144.18N/AN/AN/A
SBI Dividend Yield Fund 35,000 1.08 96.48N/AN/AN/A
SBI Healthcare Opportunities Fund 35,000 2.52 96.4840,0002026-02-23 05:17:24-12.5%
SBI Retirement Benefit Fund - Aggressive Plan 17,200 1.55 47.41N/AN/AN/A
Bandhan Large & Mid Cap Fund 10,762 0.21 29.67N/AN/AN/A

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 25Mar 24Mar 23Mar 22Mar 21
FaceValue 10.0010.0010.0010.0010.00
Basic EPS (Rs.) 665.62565.28446.78375.86325.04
Diluted EPS (Rs.) 665.62565.28446.78375.86325.04
Cash EPS (Rs.) 699.41598.77479.71406.96352.38
Book Value[Excl.RevalReserv]/Share (Rs.) 1992.071740.651500.491326.961224.55
Book Value[Incl.RevalReserv]/Share (Rs.) 1992.071740.651500.491326.961224.55
Dividend / Share (Rs.) 475.00410.00325.00275.00275.00
Revenue From Operations / Share (Rs.) 3016.072752.432517.052314.952028.24
PBDIT / Share (Rs.) 927.14800.64639.90548.20471.70
PBIT / Share (Rs.) 893.36767.15606.97517.10444.34
PBT / Share (Rs.) 887.98761.29599.44508.11435.74
Net Profit / Share (Rs.) 665.62565.28446.78375.86325.03
PBDIT Margin (%) 30.7429.0825.4223.6823.25
PBIT Margin (%) 29.6127.8724.1122.3321.90
PBT Margin (%) 29.4427.6523.8121.9421.48
Net Profit Margin (%) 22.0620.5317.7516.2316.02
Return on Networth / Equity (%) 33.4132.4729.7728.3226.54
Return on Capital Employeed (%) 42.0942.3338.5036.3733.60
Return On Assets (%) 23.9023.1220.8418.9017.98
Asset Turnover Ratio (%) 1.151.201.221.221.17
Current Ratio (X) 3.392.422.513.203.41
Quick Ratio (X) 2.761.961.972.632.72
Inventory Turnover Ratio (X) 8.549.220.830.700.72
Dividend Payout Ratio (NP) (%) 61.5957.4961.540.000.00
Dividend Payout Ratio (CP) (%) 58.6154.2757.320.000.00
Earning Retention Ratio (%) 38.4142.5138.460.000.00
Cash Earning Retention Ratio (%) 41.3945.7342.680.000.00
Interest Coverage Ratio (X) 172.37136.6685.0460.9954.83
Interest Coverage Ratio (Post Tax) (X) 124.7597.4860.3842.8238.78
Enterprise Value (Cr.) 63674.7155125.7644996.8634862.1129441.84
EV / Net Operating Revenue (X) 9.939.428.417.096.83
EV / EBITDA (X) 32.3232.4033.0929.9329.37
MarketCap / Net Operating Revenue (X) 10.199.798.777.657.39
Retention Ratios (%) 38.4042.5038.450.000.00
Price / BV (X) 15.4315.4814.7213.3412.24
Price / Net Operating Revenue (X) 10.199.798.777.657.39
EarningsYield 0.020.020.020.020.02

After reviewing the key financial ratios for Abbott India Ltd, here is a detailed analysis based on the latest available data and recent trends:

  • For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
  • For Basic EPS (Rs.), as of Mar 25, the value is 665.62. This value is within the healthy range. It has increased from 565.28 (Mar 24) to 665.62, marking an increase of 100.34.
  • For Diluted EPS (Rs.), as of Mar 25, the value is 665.62. This value is within the healthy range. It has increased from 565.28 (Mar 24) to 665.62, marking an increase of 100.34.
  • For Cash EPS (Rs.), as of Mar 25, the value is 699.41. This value is within the healthy range. It has increased from 598.77 (Mar 24) to 699.41, marking an increase of 100.64.
  • For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 1,992.07. It has increased from 1,740.65 (Mar 24) to 1,992.07, marking an increase of 251.42.
  • For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 1,992.07. It has increased from 1,740.65 (Mar 24) to 1,992.07, marking an increase of 251.42.
  • For Dividend / Share (Rs.), as of Mar 25, the value is 475.00. This value exceeds the healthy maximum of 3. It has increased from 410.00 (Mar 24) to 475.00, marking an increase of 65.00.
  • For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 3,016.07. It has increased from 2,752.43 (Mar 24) to 3,016.07, marking an increase of 263.64.
  • For PBDIT / Share (Rs.), as of Mar 25, the value is 927.14. This value is within the healthy range. It has increased from 800.64 (Mar 24) to 927.14, marking an increase of 126.50.
  • For PBIT / Share (Rs.), as of Mar 25, the value is 893.36. This value is within the healthy range. It has increased from 767.15 (Mar 24) to 893.36, marking an increase of 126.21.
  • For PBT / Share (Rs.), as of Mar 25, the value is 887.98. This value is within the healthy range. It has increased from 761.29 (Mar 24) to 887.98, marking an increase of 126.69.
  • For Net Profit / Share (Rs.), as of Mar 25, the value is 665.62. This value is within the healthy range. It has increased from 565.28 (Mar 24) to 665.62, marking an increase of 100.34.
  • For PBDIT Margin (%), as of Mar 25, the value is 30.74. This value is within the healthy range. It has increased from 29.08 (Mar 24) to 30.74, marking an increase of 1.66.
  • For PBIT Margin (%), as of Mar 25, the value is 29.61. This value exceeds the healthy maximum of 20. It has increased from 27.87 (Mar 24) to 29.61, marking an increase of 1.74.
  • For PBT Margin (%), as of Mar 25, the value is 29.44. This value is within the healthy range. It has increased from 27.65 (Mar 24) to 29.44, marking an increase of 1.79.
  • For Net Profit Margin (%), as of Mar 25, the value is 22.06. This value exceeds the healthy maximum of 10. It has increased from 20.53 (Mar 24) to 22.06, marking an increase of 1.53.
  • For Return on Networth / Equity (%), as of Mar 25, the value is 33.41. This value is within the healthy range. It has increased from 32.47 (Mar 24) to 33.41, marking an increase of 0.94.
  • For Return on Capital Employeed (%), as of Mar 25, the value is 42.09. This value is within the healthy range. It has decreased from 42.33 (Mar 24) to 42.09, marking a decrease of 0.24.
  • For Return On Assets (%), as of Mar 25, the value is 23.90. This value is within the healthy range. It has increased from 23.12 (Mar 24) to 23.90, marking an increase of 0.78.
  • For Asset Turnover Ratio (%), as of Mar 25, the value is 1.15. It has decreased from 1.20 (Mar 24) to 1.15, marking a decrease of 0.05.
  • For Current Ratio (X), as of Mar 25, the value is 3.39. This value exceeds the healthy maximum of 3. It has increased from 2.42 (Mar 24) to 3.39, marking an increase of 0.97.
  • For Quick Ratio (X), as of Mar 25, the value is 2.76. This value exceeds the healthy maximum of 2. It has increased from 1.96 (Mar 24) to 2.76, marking an increase of 0.80.
  • For Inventory Turnover Ratio (X), as of Mar 25, the value is 8.54. This value exceeds the healthy maximum of 8. It has decreased from 9.22 (Mar 24) to 8.54, marking a decrease of 0.68.
  • For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 61.59. This value exceeds the healthy maximum of 50. It has increased from 57.49 (Mar 24) to 61.59, marking an increase of 4.10.
  • For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 58.61. This value exceeds the healthy maximum of 50. It has increased from 54.27 (Mar 24) to 58.61, marking an increase of 4.34.
  • For Earning Retention Ratio (%), as of Mar 25, the value is 38.41. This value is below the healthy minimum of 40. It has decreased from 42.51 (Mar 24) to 38.41, marking a decrease of 4.10.
  • For Cash Earning Retention Ratio (%), as of Mar 25, the value is 41.39. This value is within the healthy range. It has decreased from 45.73 (Mar 24) to 41.39, marking a decrease of 4.34.
  • For Interest Coverage Ratio (X), as of Mar 25, the value is 172.37. This value is within the healthy range. It has increased from 136.66 (Mar 24) to 172.37, marking an increase of 35.71.
  • For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 124.75. This value is within the healthy range. It has increased from 97.48 (Mar 24) to 124.75, marking an increase of 27.27.
  • For Enterprise Value (Cr.), as of Mar 25, the value is 63,674.71. It has increased from 55,125.76 (Mar 24) to 63,674.71, marking an increase of 8,548.95.
  • For EV / Net Operating Revenue (X), as of Mar 25, the value is 9.93. This value exceeds the healthy maximum of 3. It has increased from 9.42 (Mar 24) to 9.93, marking an increase of 0.51.
  • For EV / EBITDA (X), as of Mar 25, the value is 32.32. This value exceeds the healthy maximum of 15. It has decreased from 32.40 (Mar 24) to 32.32, marking a decrease of 0.08.
  • For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 10.19. This value exceeds the healthy maximum of 3. It has increased from 9.79 (Mar 24) to 10.19, marking an increase of 0.40.
  • For Retention Ratios (%), as of Mar 25, the value is 38.40. This value is within the healthy range. It has decreased from 42.50 (Mar 24) to 38.40, marking a decrease of 4.10.
  • For Price / BV (X), as of Mar 25, the value is 15.43. This value exceeds the healthy maximum of 3. It has decreased from 15.48 (Mar 24) to 15.43, marking a decrease of 0.05.
  • For Price / Net Operating Revenue (X), as of Mar 25, the value is 10.19. This value exceeds the healthy maximum of 3. It has increased from 9.79 (Mar 24) to 10.19, marking an increase of 0.40.
  • For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.02.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Abbott India Ltd as of March 15, 2026 is: ₹20,415.76

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of March 15, 2026, Abbott India Ltd is Overvalued by 23.49% compared to the current share price ₹26,685.00

Intrinsic Value of Abbott India Ltd as of March 15, 2026 is: ₹23,232.43

Calculation basis:

  • Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
  • EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of March 15, 2026, Abbott India Ltd is Overvalued by 12.94% compared to the current share price ₹26,685.00

Last 5 Year EPS CAGR: 13.80%

*Investments are subject to market risks

Strength and Weakness

StrengthWeakness
  1. The stock has a high average ROCE of 39.17%, which is a positive sign.
  2. The stock has a low average Working Capital Days of 24.08, which is a positive sign.
  3. The company has higher reserves (2,363.00 cr) compared to borrowings (81.15 cr), indicating strong financial stability.
  4. The company has shown consistent growth in sales (3.69 cr) and profit (348.31 cr) over the years.
  1. The stock has a high average Cash Conversion Cycle of 24.08, which may not be favorable.

Stock Analysis

  • Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Abbott India Ltd:
    1. Net Profit Margin: 22.06%
      • Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
    2. ROCE: 42.09% (Industry Average ROCE: 16.35%)
      • ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
    3. ROE%: 33.41% (Industry Average ROE: 15.16%)
      • ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
    4. Interest Coverage Ratio (Post Tax): 124.75
      • Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
    5. Quick Ratio: 2.76
      • Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
    6. Stock P/E: 37.2 (Industry average Stock P/E: 55.17)
      • Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
    7. Total Debt / Equity: 0
      • Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
    The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
    Stock Rating:

About the Company - Qualitative Analysis

Abbott India Ltd. is a Public Limited Listed company incorporated on 22/08/1944 and has its registered office in the State of Maharashtra, India. Company's Corporate Identification Number(CIN) is L24239MH1944PLC007330 and registration number is 007330. Currently Company is involved in the business activities of Manufacture of allopathic pharmaceutical preparations. Company's Total Operating Revenue is Rs. 6409.15 Cr. and Equity Capital is Rs. 21.25 Cr. for the Year ended 31/03/2025.
INDUSTRYADDRESSCONTACT
Pharmaceuticals3, Corporate Park, Mumbai Maharashtra 400071Contact not found
Management
NamePosition Held
Mr. Munir ShaikhChairman
Mr. Kartik RajendranManaging Director
Mr. Kaiyomarz MarfatiaNon Executive Director
Mr. Ambati VenuNon Executive Director
Ms. Alison DaviesNon Executive Director
Ms. Anisha MotwaniIndependent Director
Ms. Shalini KamathIndependent Director
Mr. Sudarshan JainIndependent Director

FAQ

What is the intrinsic value of Abbott India Ltd?

Abbott India Ltd's intrinsic value (as of 15 March 2026) is ₹23232.43 which is 12.94% lower the current market price of ₹26,685.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹56,706 Cr. market cap, FY2025-2026 high/low of ₹37,000/26,000, reserves of ₹3,990 Cr, and liabilities of ₹5,694 Cr.

What is the Market Cap of Abbott India Ltd?

The Market Cap of Abbott India Ltd is 56,706 Cr..

What is the current Stock Price of Abbott India Ltd as on 15 March 2026?

The current stock price of Abbott India Ltd as on 15 March 2026 is ₹26,685.

What is the High / Low of Abbott India Ltd stocks in FY 2025-2026?

In FY 2025-2026, the High / Low of Abbott India Ltd stocks is ₹37,000/26,000.

What is the Stock P/E of Abbott India Ltd?

The Stock P/E of Abbott India Ltd is 37.2.

What is the Book Value of Abbott India Ltd?

The Book Value of Abbott India Ltd is 1,888.

What is the Dividend Yield of Abbott India Ltd?

The Dividend Yield of Abbott India Ltd is 1.78 %.

What is the ROCE of Abbott India Ltd?

The ROCE of Abbott India Ltd is 46.2 %.

What is the ROE of Abbott India Ltd?

The ROE of Abbott India Ltd is 35.7 %.

What is the Face Value of Abbott India Ltd?

The Face Value of Abbott India Ltd is 10.0.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Abbott India Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE
Explore Industry-wise Stock Analysis Reports